Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity

Nature Reviews Immunology

Volumn 3, Issue 3, 2003, Pages 211-222

  Wilson, S Brian ^a   Delovitch, Terry L ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSYLCERAMIDE; CD1 ANTIGEN; CD1D ANTIGEN;

AUTOIMMUNE DISEASE; CANCER; CELL ACTIVITY; CELL FUNCTION; CELL INTERACTION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; ANIMAL; CELL COMMUNICATION; DRUG EFFECT; IMMUNOLOGY; IMMUNOSURVEILLANCE; LYMPHOCYTE SUBPOPULATION; NEOPLASM;

ANIMALS; ANTIGENS, CD1; AUTOIMMUNE DISEASES; CELL COMMUNICATION; DENDRITIC CELLS; GALACTOSYLCERAMIDES; HUMANS; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; NEOPLASMS;

EID: 0037364854     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1028     Document Type: Review

References (113)

1. Porcelli, S. A. & Modlin, R. L. The CD1 system: antigen-presenting molecules for T-cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 17, 297-329 (1999).
2. Brossay, L. & Kronenberg, M. Highly conserved antigen-presenting function of CD1d molecules. Immunogenetics 50, 146-151 (1999).
3. Koseki, H., Imai, K., Ichikawa, T., Hayata, I. & Taniguchi, M. Predominant use of a particular α-chain in suppressor T-cell hybridomas specific for keyhole limpet hemocyanin. Int. Immunol. 1, 557-564 (1989).
4. Balk, S. P. et al. Oligoclonal expansion and CD1 recognition by human intestinal intraepithelial lymphocytes. Science 253, 1411-1415 (1991).
5. - αβ T cells demonstrates preferential use of several Vβ genes and an invariant TCR α-chain. J. Exp. Med. 178, 1-16 (1993).
6. H2 phenotype. J. Immunol. 163, 2373-2377 (1999).
7. - T lymphocytes. Science 268, 863-865 (1995). In this study, the mouse CD1d protein was identified as the restricting element for invariant natural killer T (iNKT) cells.
8. Godfrey, D. I. et al. NKT cells: facts, functions and fallacies. Immunol. Today 21, 573-583 (2000).
9. Kronenberg, M. & Gapin, L. The unconventional lifestyle of NKT cells. Nature Rev. Immunol. 2, 557-568 (2002).
10. Kawano, T. et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278, 1626-1629 (1997). This paper describes how synthetic α-galactosyl ceramides (α-GalCer) were discovered as the first known antigens for iNKT cells.
11. H2-like cytokines compared with double-negative (DN) iNKT cells.
12. Lee, P. T., Benlagha, K., Teyton, L. & Bendelac, A. Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med. 195, 637-641 (2002).
13. Delovitch, T. L. & Singh, B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7, 727-738 (1997).
14. Bach, J. F. & Chatenoud, L. Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol. 19, 131-161 (2001).
15. Bendelac, A., Rivera, M. N., Park, H.-S. & Roark, J. H. Mouse CD1-specific NK1 T cells: development, specificity and function. Annu. Rev. Immunol. 15, 535-562 (1997).
16. Bendelac, A., Hunziker, R. D. & Lantz, O. Increased interleukin-4 and immunoglobulin-E production in transgenic mice overexpressing NK1 T cells. J. Exp. Med. 184, 1285-1293 (1996).
17. Wilson, S. B. et al. Multiple differences in gene expression in regulatory Vα24JαQ T cells from identical twins discordant for type I diabetes. Proc. Natl Acad. Sci. USA 97, 7411-7416 (2000).
18. Yang, O. O. et al. CD1d an myeloid dendritic cells stimulates cytokine secretion and cytolytic activity of Vα24JαQ T cells: a feedback mechanism for immune regulation. J. Immunol. 165, 3756-3762 (2000).
19. Wilson, S. B. & Byrne, M. C. Gene expression in NKT cells: defining a functionally distinct CD1d-restricted T-cell subset. Curr. Opin. Immunol. 13, 555-561 (2001).
20. H2-cell responses can be generated in the absence of CD1d.
21. + T-cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc. Natl Acad. Sci. USA 94, 10838-10843 (1997).
22. Eberl, G. et al. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J. Immunol. 162, 6410-6419 (1999).
23. Matsuda, J. L. et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192, 741-754 (2002). This study was the first to show iNKT-cell responses ex vivo using CD1d tetramers loaded with α-GalCer.
24. Matsuda, J. L. et al. Homeostasis of Vα14i NKT cells. Nature Immunol. 3, 966-974 (2002).
25. Sharif, S. et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nature Med. 7, 1057-1062 (2001). Together with references 26, 40 and 41, this study showed the protective effect of α-GalCer in nonobese diabetic (NOD) mice.
26. Naumov, Y. N. et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic-cell subsets. Proc. Natl Acad. Sci. USA 98, 13838-13843 (2001). This study showed that the protective effect of α-GalCer therapy in NOD mice was, in part, due to the recruitment of tolerogenic dendritic cells (DCs) to the pancreatic lymph nodes.
27. Nieuwenhuis, E. E. et al. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nature Med. 8, 588-593 (2002). This study showed the importance of iNKT cells and monocytes for the acute control of infections in the lung.
28. Apostolou, I. et al. Murine natural killer T (NKT) cells contribute to the granulamatous reaction caused by mycobacterial cell walls. Proc. Natl Acad. Sci. USA 96, 5141-5146 (1999).
29. Kita, H. et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123, 1031-1043 (2002).
30. + and DN iNKT cells.
31. Faunce, D. E., Sonoda, K. H. & Stein-Streilein, J. MIP-2 recruits NKT cells to the spleen during tolerance induction. J. Immunol. 166, 313-321 (2001).
32. Sharif, S., Arreaza, G. A., Zucker, P., Mi, Q. S. & Delovitch, T. L. Regulation of autoimmune disease by natural killer T cells. J. Mol. Med. 80, 290-300 (2002).
33. Cameron, M. J. et al. Differential expression of CC-chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J. Immunol. 165, 1102-1110 (2000).
34. +-like thymocytes in the NOD mouse. Eur. J. Immunol. 26, 2989-2998 (1996). This report was the first demonstration of decreased frequency and loss of function of iNKT cells in NOD mice.
35. Falcone, M. et al. A defect in interleukin-12-induced activation and interferon-γ secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus. J. Exp. Med. 190, 963-972 (1999).
36. H1 bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature 391, 177-181 (1998). This report was the first demonstration of decreased frequency and loss of function of iNKT cells in humans with insulin-dependent diabetes mellitus.
37. + NK T cells associated with disease development in autoimmune-prone mice. J. Immunol. 156, 4035-4040 (1996).
38. Kukreja, A. et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109, 131-140 (2002).
39. - T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 46, 572-582 (1997).
40. Wang, B., Geng, Y. B. & Wang, C. R. Cd1-restricted NKT cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med. 194, 313-320 (2001). Together with references 26 and 50, this study showed an exacerbation of autoimmune diabetes in CD1d-deficient NOD mice.
41. Hong, S. et al. The natural killer T-cell ligand α -galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nature Med. 7, 1052-1056 (2001).
42. Mempel, M. et al. Comparison of the T-cell patterns in leprous and cutaneous sarcoid granulomas. Presence of Vα24-invariant natural killer T cells in T-cell-reactive leprosy together with a highly biased T-cell receptor Vα repertoire Am. J. Pathol. 157, 509-523 (2000).
43. Grattan, M., Mi, Q. S., Meagher, C. & Delovitch, T. L. Congenic mapping of the diabetogenic locus Idd4 to a 5.2-cM region of chromosome 11 in NOD mice: identification of two potential candidate subloci. Diabetes 51, 215-223 (2002).
44. Lee, P. T. et al. Testing the NKT-cell hypothesis of human IDDM pathogenesis. J. Clin. Invest. 110, 793-800 (2002).
45. + T cells observed in type 1 diabetes. Diabetes Care 25, 1818-1823 (2002).
46. Chatenoud, L. Do NKT cells control autoimmunity? J. Clin. Invest. 110, 747-748 (2002).
47. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187, 1047-1056 (1998). This study showed the importance of iNKT cells, IL-4 and IL-10 for protecting NOD mice from autoimmune diabetes by transfer of iNKT cells into naive pre-diabetic NOD mice.
48. Lehuen, A. et al. Overexpression of natural killer T cells protects Vα14-Jα281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188, 1831-1839 (1998).
49. - T-cell-defective IL-4 production in the non-obese diabetic mouse. Int. Immunol. 8, 1751-1758 (1996).
50. Shi, F. D. et al. Germ-line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc. Natl Acad. Sci. USA 98, 6777-6782 (2001).
51. Beaudoin, L. et al. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic β-cells. Immunity 17, 725-736 (2002). This study showed an important contribution of iNKT cells to the inhibition of pathogenic islet-specific T cells.
52. Sumida, T. et al. Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis. J. Exp. Med. 182, 1163-1168 (1995). This early study was the first to show a paucity of iNKT cells in a human autoimmune disorder.
53. + T cells that promptly produce interleukin-4. Proc. Natl Acad. Sci. USA 92, 11931-11934 (1995).
54. Illes, Z. et al. Differential expression of NKT cell Vα24JαQ invariant TCR chains in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J. Immunol. 164, 4375-4381 (2000).
55. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100, 144-148 (2001).
56. Zeng, D., Lee, M. K., Tung, J., Brendolan, A. & Strober, S. Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J. Immunol. 164, 5000-5004 (2000).
57. Nagane, Y., Utsugisawa, K., Obara, D. & Tohgi, H. NKT-associated markers and perforin in hyperplastic thymuses from patients with myasthenia gravis. Muscle Nerve 24, 1359-1364 (2001).
58. Saubermann, L. J. et al. Activation of natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 119, 119-128 (2000).
59. Singh, A. K. et al. Natural killer T-cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194, 1801-1811 (2001).
60. Jahng, A. W. et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194, 1789-1799 (2001). This study showed the Janus nature of iNKT cells in experimental allergic encephalomyelitis (EAE).
61. Pal, E. et al. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NK T cells. J. Immunol. 166, 662-668 (2001).
62. H-cell phenotype of iNKT cells and the adaptive immune response.
63. H2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J. Immunol. 166, 6012-6018 (2001).
64. Cui, J. et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626 (1997).
65. Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000). This study showed the importance of iNKT cells for the surveillance of subsets of endogenously occurring tumours.
66. Kitamura, H. et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189, 1121-1128 (1999).
67. - NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J. Immunol. 163, 93-101 (1999).
68. - T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99, 1259-1266 (2002). This study dissected the temporal requirements for IFN-γ, iNKT cells, DCs and NK cells for tumour surveillance.
69. Crowe, N. Y., Smyth, M. J. & Godfrey, D. I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196, 119-127 (2002).
70. Carnaud, C. et al. Cutting edge. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163, 4647-4650 (1999).
71. Fernandez, N. C. et al. Dendritic cells directly trigger NK-cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Med. 5, 405-411 (1999).
72. Terabe, M. et al. NKT-cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunol. 1, 515-520 (2000). This study showed the inhibitory role that iNKT cells can sometimes have during tumour surveillance.
73. H2-cell-like phenotype by iNKT cells in patients with prostate cancer.
74. Ludewig, B. et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191, 795-804 (2000).
75. - T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190, 705-715 (1999).
76. Mach, N. et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60, 3239-3246 (2000).
77. Mathis, D., Vence, L. & Benoist, C. β-cell death during progression to diabetes. Nature 414, 792-798 (2001).
78. Hoglund, P. et al. Initiation of autoimmune diabetes by developmentally regulated presentation of islet-cell antigens in the pancreatic lymph nodes. J. Exp. Med. 189, 331-339 (1999). This study showed the importance of regional lymph-node antigen presentation for the development of autoimmune diabetes in mice.
79. Green, E. A. & Flavell, R. A. The temporal importance of TNF-α expression in the development of diabetes. Immunity 12, 459-469 (2000). This study showed the importance of inflammatory cytokine secretion and rate of cell death in promoting autoimmune diabetes in mice.
80. Sauter, B. et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423-434 (2000). This study showed that the development of DC effector function depends on the nature of the cell that a DC encounters.
81. Steinman, R. M., Turley, S., Mellman, I. & Inaba, K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191, 411-416 (2000).
82. Hawiger, D. et al. Dendritic cells induce peripheral T-cell unresponsiveness under steady-state conditions in vivo. J. Exp. Med. 194, 769-779 (2001).
83. Steinman, R. M. & Nussenzweig, M. C. Inaugural article. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T-cell tolerance. Proc. Natl Acad. Sci. USA 99, 351-358 (2002).
84. Clare-Salzler, M. J., Brooks, J., Chai, A., Van Herle, K. & Anderson, C. Prevention of diabetes in nonobese diabetic mice by dendritic-cell transfer. J. Clin. Invest. 90, 741-748 (1992). This was the first study to show the protective effect of myeloid DCs derived from the pancreatic lymph nodes in NOD mice.
85. Johnson, E. A., Silveira, P., Chapman, H. D., Leiter, E. H. & Serreze, D. V. Inhibition of autoimmune diabetes in nonobese diabetic mice by transgenic restoration of H2-E MHC class II expression: additive, but unequal, involvement of multiple APC subtypes. J. Immunol. 167, 2404-2410 (2001).
86. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238 (2001).
87. + T cells. Nature Immunol. 2, 1010-1017 (2001).
88. Menges, M. et al. Repetitive injections of dendritic cells matured with tumor-necrosis factor-α induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. 195, 15-21 (2002). This study showed the tolerogenic function of DCs.
89. Banchereau, J. et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811 (2000).
90. Pulendran, B., Palucka, K. & Banchereau, J. Sensing pathogens and tuning immune responses. Science 293, 253-256 (2001).
91. H2-promoting effector functions for human myeloid and lymphoid DCs, respectively.
92. Liu, Y. J., Kanzler, H., Soumelis, V. & Gilliet, M. Dendritic-cell lineage, plasticity and cross-regulation. Nature Immunol. 2, 585-589 (2001).
93. Shreedhar, V. et al. Dendritic cells require T cells for functional maturation in vivo. Immunity 11, 625-636 (1999). This study showed the importance of continued T-cell-DC cross-talk for DC survival.
94. Vincent, M. S. et al. CD1-dependent dendritic-cell instruction. Nature Immunol. 3, 1163-1168 (2002).
95. Kadowaki, N. et al. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J. Exp. Med. 193, 1221-1226 (2001).
96. Ikarashi, Y. et al. Dendritic-cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon-γ production. J. Exp. Med. 194, 1179-1186 (2001).
97. Leslie, D. S. et al. CD1-mediated γδ T-cell maturation of dendritic cells. J. Exp. Med. 196, 1575-1584 (2002).
98. Mi, Q.-S., Meagher, C. & Delovitch, T. L. in Novartis Foundation Symposium 252. Generation and Effector Functions of Regulatory Lymphocytes (Wiley, Europe) (in the press).
99. Cruikshank, W. W., Kornfeld, H. & Center, D. M. Interleukin-16. J. Leukocyte Biol. 67, 757-766 (2000).
100. Mars, L. T. et al. Vα14-Jα281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J. Immunol. 168, 6007-6011 (2002).
101. Sonoda, K. H. et al. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 190, 1215-1226 (1999). This study showed the importance of iNKT cells and myeloid antigen-presenting cells expressing CD1d for the generation of antigen-specific tolerance.
102. Sonoda, K. H. et al. NK T-cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J. Immunol. 166, 42-50 (2001).
103. Takahashi, K., Honeyman, M. C. & Harrison, L. C. Impaired yield, phenotype and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J. Immunol. 161, 2629-2635 (1998).
104. Serreze, D. V., Gaskins, H. R. & Leiter, E. H. Defects in the differentiation and function of antigen-presenting cells in NOD/Lt mice. J. Immunol. 150, 2534-2543 (1993).
105. - T-cell responses. Nature Med. 7, 206-214 (2001).
106. H1 cytokine: IL-12 and diabetes in NOD mice. Ann. NY Acad. Sci. 795, 241-249 (1996).
107. Alleva, D. G. et al. Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-α and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. Diabetes 49, 1106-1115 (2000).
108. Poligone, B. et al. Elevated NF-κB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function J. Immunol. 188, 188-196 (2002).
109. Osman, Y. et al. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol. 30, 1919-1928 (2000).
110. Giaccone, G. et al. A Phase I study of the NKT-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8, 3702-3709 (2002).
111. + NKT cells expand following administration of α -galactosylceramide-pulsed dendritic cells. Vox. Sang. 83, 250-253 (2002).
112. H2 colitis model resembling ulcerative colitis is mediated by IL-13-producing NK-T cells. Immunity 17, 629-638 (2002).
113. Fujii, S.-I., Shimizu, K., Kronenberg, M. & Steinman, R. M. Prolonged interferon-γ-producing NKT response induced with α-galactosylceramide-loaded DCs. Nature Immunol. 3, 867-874 (2002).